An Open-label, Single-dose Study to Evaluate Etelcalcetide (AMG 416) in Paediatric Subjects Aged 2 to Less Than 18 Years With Secondary Hyperparathyroidism (sHPT) Receiving Maintenance Haemodialysis
Phase of Trial: Phase I
Latest Information Update: 10 Oct 2017
At a glance
- Drugs Etelcalcetide (Primary)
- Indications Secondary hyperparathyroidism
- Focus Adverse reactions
- Sponsors Amgen
- 10 Jun 2017 Biomarkers information updated
- 07 Apr 2017 Status changed from not yet recruiting to recruiting.
- 24 Jan 2017 Planned initiation date changed from 1 Dec 2016 to 1 Feb 2017.